VA
IRWD icon

Vident Advisory’s Ironwood Pharmaceuticals IRWD Stock Holding History

Vident Advisory’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$647K Buy
+184,337
New +$756K 0.01% 1114
2024
Q1 		– Sell
-19,619
Closed -$224K – 1366
2023
Q4 		$224K Buy
19,619
+3,743
+24% +$37K 0.01% 1160
2023
Q3 		$153K Buy
+15,876
New +$156K ﹤0.01% 1161

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Vident Advisory's IRWD Position: Q1 2026 in Review

Vident Advisory opened a new position in Ironwood Pharmaceuticals (IRWD) in Q1 2026: 184,337 shares worth $647K. The stake represents 0.01% of the portfolio and ranks #1114 among its holdings. This is a return to the name: Vident Advisory previously reported a position in IRWD as recently as Q4 2023.

Vident Advisory first reported a position in IRWD in Q3 2023 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Vident Advisory held 184,337 shares of Ironwood Pharmaceuticals worth $647K as of Q1 2026.
  • Ironwood Pharmaceuticals was a new Vident Advisory position in Q1 2026.
  • Ironwood Pharmaceuticals made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #1114 holding.
  • Vident Advisory first reported a position in Ironwood Pharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.